Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Eureka! New P2 trial - Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC). First rec'd Feb 23 30 patients and not recruiting yet w ORR as the primary endpoint. Interesting, in that listening to the RBC Capital CC last week Dr. Raj was talking of a P1 w 10 pts to be followed by a 100 pt P2. I guess we may find out more at the quarterly meeting.